Flashcards - Genetics
Chromosome 3
von Hippel-Lindau disease, renal cell carcinoma
Chromosome 4
ADPKD with PKD2 defect, Huntington disease
Chromosome 5
Cri-du-chat syndrome, familial adenomatous polyposis
Chromosome 7
Williams syndrome, cystic fibrosis
Chromosome 9
Friedreich ataxia (GAA)
Chromosome 11
Wilms tumor
Chromosome 13
Patau syndrome, Wilson disease
Chromosome 15
Prader-Willi (paternal deletion) syndrome, Angelman (maternal deletion) syndrome
Chromosome 16
ADPKD with PKD1 defect
Chromosome 17
Neurofibromatosis type 1
Chromosome 18
Edwards syndrome
Chromosome 21
Down syndrome
Chromosome 22
Neurofibromatosis type 2, DiGeorge syndrome (22q11)
Chromosome X
Fragile X syndrome, X-linked agammaglobulinemia, Klinefelter syndrome (XXY)
Codominance
Both alleles contribute to the phenotype of the heterozygote.
Variable expressivity
Phenotype varies among individuals with same genotype.
Incomplete penetrance
Not all individuals with a mutant genotype show the mutant phenotype.
Pleiotropy
One gene contributes to multiple phenotypic effects.
Anticipation
Increased severity or earlier onset of disease in succeeding generations.
Loss of heterozygosity
If a patient inherits or develops a mutation in a tumor suppressor gene, the complementary allele must be deleted/mutated before cancer develops. This is not true of oncogenes.
Dominant negative mutation
Exerts a dominant effect. A heterozygote produces a nonfunctional altered protein that also prevents the normal gene product from functioning.
Linkage disequilibrium
Tendency for certain alleles at 2 linked loci to occur together more or less often than expected by chance. Measured in
a population, not in a family, and often varies in different populations.
Mosaicism
Presence of genetically distinct cell lines in the same individual.
Somatic mosaicism—mutation arises from mitotic errors after fertilization and propagates through multiple tissues or organs.
Gonadal mosaicism—mutation only in egg or sperm cells.
Locus heterogeneity
Mutations at different loci can produce a similar phenotype.
Allelic heterogeneity
Different mutations in the same locus produce the same phenotype.
Heteroplasmy
Presence of both normal and mutated mtDNA, resulting in variable expression in mitochondrially inherited disease.
Uniparental disomy
Offspring receives 2 copies of a chromosome from 1 parent and no copies from the other parent. Heterodisomy (heterozygous) indicates a meiosis I error. Isodisomy (homozygous) indicates a meiosis II error or postzygotic chromosomal duplication of one of a pair of chromosomes, and loss of the other of the original pair.
Menkes disease
XL - defective ATP7A - decreased lysyl oxidase activity - kinky brittle hair, growth retardation, hypotonia
HNPCC/Lynch Syndrome
DNA mismatch repair mutation (MLH1, MSH2, MSH6, PMS2)
Von Recklinghausen
NF1 - neurofibromas, optic nerve gliomas, cafe au lait spots
Sturge-Weber
leptomeningial and facial angiomas (portwine stains), tramtrack calcifications of skull
Tuberous sclerosis
AD - hamartomas - kidney, liver, pancreas cysts and CNS involvement
Hirshsprung Disease
defective RET gene
Osler-Weber-Rendu
hereditary hemmoraghic telangiectasia - musoca involvement
Wiskott-Aldrich syndrome
triad of eczema, recurrent infections, thrombocytopenia
Fragile X syndrome
FMR1 gene - CGG trinucleotide repeats
Myotonic type 1 muscular dystrophy
AD - CTC trinucleotide repeat
Rb
tumor suppressor gene - active (hypophosphorylated) stops G1/S transition - holds back E2F - hyperphosphorylated in retinoblastoma, osteosarcoma
p53
inducer of apoptosis - Li Fraumeni
bcl2
inhibits apoptosis - BAX
K-ras
proto-oncogene
c-myc
nuclear phosphoprotein, transcription activator for proliferation/differentiation/apoptosis - Burkitt lymphoma
t(8:14)
c-myc:Ig - Burkitt lymphoma
t(9:22)
bcr:abl
t(11:14)
cyclin-D1:Ig - mantle cell lymphoma
t(14:18)
Ig:bcl-2 - follicular lymphoma
t(15:17)
PML:RARa - acute promyelocytic leukemia
BCR-ABL
Tyrosine kinase - CML, ALL
BRAF
Serine/threonine kinase - Melanoma, non-Hodgkin lymphoma
c-kit
Cytokine growth factor receptor - Gastrointestinal stromal tumor (GIST)
HER2/neu (c-erbB2)
Tyrosine kinase - Breast, ovarian, and gastric carcinomas
L-myc
Transcription factor - Lung tumor
N-myc
Transcription factor - Neuroblastoma
RAS
GTPase - Colon cancer, lung cancer, pancreatic cancer
RET
Tyrosine kinase -
gain of function - MEN 2A and 2B, medullary thyroid cancer
loss of function - Hirschsprungs
APC
Colorectal cancer (associated with FAP)
BRCA1/BRCA2
Breast and ovarian cancer - DNA repair protein
DCC
Colon cancer - DCC—Deleted in Colon Cancer
DPC4/SMAD4
Pancreatic cancer - DPC—Deleted in Pancreatic Cancer
MEN1
MEN 1 Menin
NF1
NeuroFibromatosis type 1 - Ras GTPase activating protein (neurofibromin)
NF2
NeuroFibromatosis type 2 - Merlin (schwannomin) protein
p16
Melanoma - Cyclin-dependent kinase inhibitor 2A
p53
Li-Fraumeni syndrome - Transcription factor for p21, blocks G1 S phase
PTEN
Breast cancer, prostate cancer, endometrial
TSC1
Tuberous sclerosis - Hamartin protein
TSC2
Tuberous sclerosis - Tuberin protein
VHL
AD - ubiquitin ligase component - hemangioblastomas in retina/cerebellum, cysts/neoplasms in kidney, liver, pancreas, renal cell carcinoma - Inhibits hypoxia inducible factor 1a -
WT1/WT2
Wilms Tumor (nephroblastoma)
t(11:22)
Ewings Sarcoma - EWS-FLI 1
mRNA polyadenylation 3’
3’ end with AAUAAA, cleaves pre-RNA a few bits downstream and adds 20-250 adenosine residues (poly A tail)
mRNA 5’ cap
add guanine triphosphate to 5’ –> catalyzed by guanylyltransferase –> methylation by guanine-7-methyltransferase –> 7-methylguanosine - prevents degradation